20/20 Biolabs (NASDAQ:AIDX – Get Free Report) is one of 233 publicly-traded companies in the “Healthcare Providers & Services” industry, but how does it contrast to its competitors? We will compare 20/20 Biolabs to related businesses based on the strength of its risk, dividends, earnings, profitability, analyst recommendations, valuation and institutional ownership.
Profitability
This table compares 20/20 Biolabs and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| 20/20 Biolabs | N/A | N/A | N/A |
| 20/20 Biolabs Competitors | -7.87% | -135.89% | -1.58% |
Analyst Recommendations
This is a breakdown of current ratings for 20/20 Biolabs and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| 20/20 Biolabs | 1 | 0 | 1 | 0 | 2.00 |
| 20/20 Biolabs Competitors | 1880 | 7755 | 13394 | 833 | 2.55 |
20/20 Biolabs presently has a consensus target price of $5.00, suggesting a potential upside of 2,517.80%. As a group, “Healthcare Providers & Services” companies have a potential upside of 12.79%. Given 20/20 Biolabs’ higher possible upside, analysts clearly believe 20/20 Biolabs is more favorable than its competitors.
Insider & Institutional Ownership
56.7% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 27.7% of 20/20 Biolabs shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares 20/20 Biolabs and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| 20/20 Biolabs | $2.05 million | -$3.74 million | -0.35 |
| 20/20 Biolabs Competitors | $19.21 billion | $301.67 million | -1.66 |
20/20 Biolabs’ competitors have higher revenue and earnings than 20/20 Biolabs. 20/20 Biolabs is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
About 20/20 Biolabs
20/20 BioLabs is a clinical laboratory company that has provided diagnostic testing services, with a focus on infectious diseases. Its offerings have included COVID-19 testing, such as molecular and antibody-based tests, along with related laboratory services. The company became known during the COVID-19 pandemic, when it supported demand for testing in the United States. Publicly available information about its broader operations and leadership is limited.
Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.
